| Title | Usefulness of immature platelet fraction for the clinical evaluation of myelodysplastic syndromes. | | Author(s) | Saigo K, Takenokuchi M, Imai J, Numata K, Isono S, Zenibayashi M, Tanioka H, Yoshioka T, Nishizawa A, Takada M, Nomura T, Kubota Y | | Institution | Faculty of Pharmacological Science, Himeji Dokkyo University, Himeji Department of Internal Medicine, Kakogawa Municipal Hospital, Kakogawa. | | Source | Lab Hematol 2009; 15(2):13-6. | | Abstract | Ratios of young platelets or reticulated platelets can be routinely obtained as an immature platelet fraction (IPF) with the XE-2100 automated hematology analyzer (Sysmex, Kobe, Japan). We combined IPF analysis of 31 patients with myelodysplastic syndrome (MDS) with a complete blood count, a bone marrow examination, and a chromosome analysis. The patients with >40 x 109/L platelets were classified as group A, and those with >/=40 x 109/L were placed in group B. The 2 groups were subclassified as A1 or B1 for patients with an IPF of <10% and as A2 or B2 for those with an IPF >/=10%. Categories A1, A2, B1, and B2 comprised 12 patients, 6 patients, 7 patients, and 6 patients, respectively. Patients with a relatively high IPF (>10%) (category A2 or B2) showed distinctive characteristics. Group B2 showed a higher frequency of chromosomal abnormalities than B1 (P = .029), and group A2 tended to show a higher incidence of clinical improvement than A1 (P = .08). IPF determination may be clinically useful for the assessment of prognosis for MDS patients. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19561008 |
|
